Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05515029CT.gov Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Juvenile Myelomonocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vedolizumab (this asset) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P3 | CCC · 55 |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Thiotepa | St. Jude Children's Research Hospital | P3 | BBB |
| Fludarabine | Children's Oncology Group | P3 | BB |
| Cyclosporin A | Case Comprehensive Cancer Center | P3 | BB |
| Nivestim | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Tacrolimus | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Rituximab | Masonic Cancer Center, University of Minnesota | P3 | BB |
+36 more in the Juvenile Myelomonocytic Leukemia cohort
Other indications for Vedolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoma | — | P3 | B · 59 |
| Colitis | — | P2 | B · 58 |
| Acute Biphenotypic Leukemia | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vedolizumab in Juvenile Myelomonocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vedolizumab-juvenile-myelomonocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →